The aliens inside us: HERV-W endogenous retroviruses and multiple sclerosis

Abstract

Two human endogenous retroviruses of the HERV-W family are proposed as multiple sclerosis (MS) co-factors: MS-associated retrovirus (MSRV) and ERVWE1, whose env proteins showed several potentially neuropathogenic features, in vitro and in animal models. Phase II clinical trials against HERV-Wenv are ongoing. HERV-W/MSRV was repeatedly found in MS patients, in striking parallel with MS stages, active/remission phases, and therapy outcome. The HERV-Wenv protein is highly expressed in active MS plaques. Early MSRV presence in spinal fluids predicted worst MS progression 10 years in advance. Effective anti-MS therapies strongly reduced MSRV/Syncytin-1/HERV-W expression. The Epstein–Barr virus (EBV) activates HERV-W/MSRV in vitro and in vivo, in patients with infectious mononucleosis and controls with high anti-EBNA1-IgG titers. Thus, the two main EBV/MS links (infectious mononucleosis and high anti-EBNA1-IgG titers) are paralleled by activation of HERV-W/MSRV. It is hypothesized that EBV may act as initial trigger of future MS, years later, by activating MSRV, which would act as direct neuropathogenic effector, before and during MS.

Keywords

HERV-W/MSRV/Syncytin-1 human endogenous retroviruses MS pathogenesis biomarker MS therapy dual virus hypothesis

Get full access to this article

View all access options for this article.

References

Cusick

Libbey

Fujinami

RS.

Multiple sclerosis: Autoimmunity and viruses. Curr Opin Rheumatol 2013; 25: 496–501.

Tao

Simpson

Jr Taylor

et al . Association between human herpesvirus & human endogenous retrovirus and MS onset & progression. J Neurol Sci 2017; 372: 239–249.

Fernández-Menéndez

Fernández-Morán

Fernández-Vega

et al . Epstein–Barr virus and multiple sclerosis. From evidence to therapeutic strategies. J Neurol Sci 2016; 361: 213–219.

Dolei

Endogenous retroviruses and human disease. Expert Rev Clin Immunol 2006; 2: 149–167.

Mameli

Poddighe

Mei

et al . Expression and activation by Epstein–Barr virus of human endogenous retroviruses-W in blood cells and astrocytes: Inference for multiple sclerosis. PLoS ONE 2012; 7: e44991.

Dolei

Uleri

Ibba

et al . The aliens inside human DNA: HERV-W/MSRV/syncytin-1 endogenous retroviruses and neurodegeneration. J Infect Dev Ctries 2015; 9: 577–587.

Küry

Nath

Créange

et al . Human endogenous retroviruses and neurological diseases: Pathogenes within human genome interplay with environmental factors. Lancet Neurol, in review.

Perron

Geny

Laurent

et al . Leptomeningeal cell line from multiple sclerosis with reverse transcriptase activity and viral particles. Res Virol 1989; 140: 551–561.

Lee

et al . Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature 2000; 403: 785–789.

10.

Dolei

Perron

The multiple sclerosis-associated retrovirus and its HERV-W endogenous family: A biological interface between virology, genetics, and immunology in human physiology and disease. J Neurovirol 2009; 15: 4–13.

11.

Antony

Deslauriers

Bhat

et al . Human endogenous retroviruses and multiple sclerosis: Innocent bystanders or disease determinants? Biochim Biophys Acta 2011; 1812: 162–176.

12.

Firouzi

Rolland

Michel

et al . Multiple sclerosis-associated retrovirus particles cause T lymphocyte-dependent death with brain hemorrhage in humanized SCID mice model. J Neurovirol 2003; 9: 79–93.

13.

Antony

Van Marle

Opii

et al . Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci 2004; 7: 1088–1095.

14.

Arru

Mameli

Astone

et al . Multiple sclerosis and HERV-W/MSRV: A multicentric study. Int J Biomed Sci 2007; 3: 292–297.

15.

Mameli

Astone

Arru

et al . Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-associated retrovirus/HERV-W endogenous retrovirus, but not Human herpesvirus 6. J Gen Virol 2007; 88: 264–274.

16.

Mameli

Madeddu

Mei

et al . Activation of MSRV-type endogenous retroviruses during infectious mononucleosis and Epstein–Barr virus latency: The missing link with multiple sclerosis? PLoS ONE 2013; 8: e78474.

17.

Uleri

Mei

Mameli

et al . HIV Tat acts on endogenous retroviruses of the W family and this occurs via Toll-like receptor 4: Inference for neuroAIDS. AIDS 2014; 28: 2659–2670.

18.

Uleri

Piu

Caocci

et al . The EGF epidermal growth factor counteracts Tat modulation of human endogenous retroviruses of the W family in astrocytes. J Neurovirol 2017; 23: 587–592.

19.

Serra

Mameli

Arru

et al . In vitro modulation of the multiple sclerosis (MS)-associated retrovirus (MSRV) by cytokines: Implications for MS pathogenesis. J Neurovirol 2003; 9: 637–643.

20.

Saresella

Rolland

Marventano

et al . Multiple sclerosis-associated retroviral agent (MSRV)-stimulated cytokine production in patients with relapsing-remitting multiple sclerosis. Mult Scler 2009; 15: 443–447.

21.

Perron

Dougier-Reynaud

Lomparski

et al . Human endogenous retrovirus protein activates innate immunity and promotes experimental allergic encephalomyelitis in mice. PLoS ONE 2013; 8: e80128.

22.

Curtin

Perron

Kromminga

et al . Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein. MAbs 2015; 7: 265–275.

23.

Dolei

Serra

Mameli

et al . Multiple sclerosis-associated retrovirus (MSRV) in Sardinian MS patients. Neurology 2002; 58: 471–473.

24.

Perron

Germi

Bernard

et al . Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler 2012; 18: 1721–1736.

25.

Sotgiu

Arru

Söderström

et al . Multiple sclerosis-associated retrovirus and optic neuritis. Mult Scler 2006; 12: 357–359.

26.

Sotgiu

Mameli

Serra

et al . Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis. Mult Scler 2010; 16: 1248–1251.

27.

Mameli

Serra

Astone

et al . Inhibition of multiple-sclerosis-associated retrovirus as biomarker of interferon therapy. J Neurovirol 2008; 14: 73–77.

28.

Arru

Leoni

Pugliatti

et al . Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: A longitudinal cohort study. Mult Scler 2014; 20: 174–182.

29.

Morandi

Tanasescu

Tarlinton

et al . The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis. PLoS ONE 2017; 12: e0172415.

30.

Garcia-Montojo

Dominguez-Mozo

Arias-Leal

et al . The DNA copy number of human endogenous retrovirus-W (MSRV-type) is increased in multiple sclerosis patients and is influenced by gender and disease severity. PLoS ONE 2013; 8: e53623.

31.

Sotgiu

Serra

Mameli

et al . Multiple sclerosis (MS)-associated retrovirus and MS prognosis: An observational study. Neurology 2002; 59: 1071–1073.

32.

Sotgiu

Arru

Mameli

et al . MSRV in early multiple sclerosis: A six-year follow-up of a Sardinian cohort. Mult Scler 2006; 12: 698–703.

33.

Mameli

Poddighe

Astone

et al . Novel reliable real-time PCR for differential detection of MSRVenv and syncytin-1 in RNA and DNA from patients with multiple sclerosis. J Virol Methods 2009; 161: 98–106.

34.

Van Horssen

Van der Pol

Nijland

et al . Human endogenous retrovirus W in brain lesions: Rationale for targeted therapy in multiple sclerosis. Mult Scler Relat Disord 2016; 8: 11–18.

35.

Petersen

Møller-Larsen

Thiel

et al . Effects of interferon-beta therapy on innate and adaptive immune responses to the human endogenous retroviruses HERV-H and HERV-W, cytokine production, and the lectin complement activation pathway in multiple sclerosis. J Neuroimmunol 2009; 215: 108–116.